24/7 Market News Snapshot 10 December, 2024 – Akoya BioSciences, Inc. Common Stock (NASDAQ:AKYA)

December 10, 2024

DENVER, Colo., 10 December, 2024 (247marketnews.com) – (Nasdaq:AKYA) are discussed in this article.
Akoya BioSciences, Inc. (Nasdaq:AKYA), recognized as a leader in spatial biology, is making significant strides in the biotechnology sector, highlighted by a notable 16.47% increase in its stock price during pre-market trading, now valued at $2.609. This positive momentum is backed by a trading volume of 2.14 million shares, indicating a heightened interest among investors and positive market sentiment towards the company’s growth trajectory.

In a strategic move further solidifying its industry position, Akoya has entered an exclusive global license agreement with NeraCare to develop and commercialize the innovative Immunoprint test, a pioneering laboratory test for melanoma prognosis. This partnership builds upon a previously established research collaboration, giving Akoya exclusive rights to advance, market, and commercialize the Immunoprint assay for both clinical research and diagnostic use.

Melanoma represents an urgent global health challenge, with over 235,000 new cases diagnosed annually. This partnership aims to address a critical need, particularly for early-stage melanoma patients who, despite surgical interventions, often lack effective post-surgery treatment options. The Immunoprint test is specifically designed to identify patients at high risk of relapse, thus expanding treatment avenues for those affected.

Friedrich Ackermann, Co-Founder of NeraCare, emphasized the strengths of the collaboration, stating, “By combining Akoya’s cutting-edge technology with our rigorous clinical validation of the Immunoprint assay, we aim to significantly expand access to vital therapies for early-stage melanoma patients globally.” Akoya’s CEO, Brian McKelligon, highlighted the transformative potential of this alliance in enhancing melanoma patient care and addressing pressing treatment gaps.

As Akoya continues to attract investor interest and advance its clinical strategies, the company remains committed to making impactful contributions to the field of spatial biology and improving patient outcomes worldwide.

Related news for (AKYA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.